SD Biosensor Bilan de santé

Santé financière contrôle des critères 4/6

SD Biosensor possède un total de capitaux propres de ₩2,912.5B et une dette totale de ₩505.5B, ce qui porte son ratio d'endettement à 17.4%. Son actif total et son passif total sont ₩3,767.7B et de ₩855.2B.

Informations clés

17.4%

Ratio d'endettement

₩505.45b

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	₩532.45b
Fonds propres	₩2.91t
Total du passif	₩855.22b
Total des actifs	₩3.77t

Mises à jour récentes de la santé financière

Would SD Biosensor (KRX:137310) Be Better Off With Less Debt?

Aug 08

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de A137310 ( ₩928.2B ) dépassent ses passifs à court terme ( ₩159.3B ).

Passif à long terme: Les actifs à court terme de A137310 ( ₩928.2B ) dépassent ses passifs à long terme ( ₩695.9B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: A137310 dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Données insuffisantes pour déterminer si le ratio d'endettement de A137310 a diminué au cours des 5 dernières années.

Couverture de la dette: La dette de A137310 est bien couverte par le flux de trésorerie opérationnel ( 32.5% ).

Couverture des intérêts: Données insuffisantes pour déterminer si les paiements d'intérêts de A137310 sur sa dette sont bien couverts par l'EBIT.

SD Biosensor Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Would SD Biosensor (KRX:137310) Be Better Off With Less Debt?

Recent updates

Third quarter 2024 earnings released: EPS: ₩532 (vs ₩552 loss in 3Q 2023)

What SD Biosensor, Inc's (KRX:137310) 25% Share Price Gain Is Not Telling You

Second quarter 2024 earnings released: ₩153 loss per share (vs ₩806 loss in 2Q 2023)

Would SD Biosensor (KRX:137310) Be Better Off With Less Debt?

Insufficient Growth At SD Biosensor, Inc (KRX:137310) Hampers Share Price

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: ₩91.00 loss per share (vs ₩2,177 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Insufficient Growth At SD Biosensor, Inc (KRX:137310) Hampers Share Price

Upcoming dividend of ₩290 per share at 8.7% yield

Third quarter 2023 earnings released: ₩552 loss per share (vs ₩4,166 profit in 3Q 2022)

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 23%

New minor risk - Share price stability

SD Biosensor, Inc has completed a Follow-on Equity Offering in the amount of KRW 227.8 billion.

Upcoming dividend of ₩700 per share at 7.5% yield

Now 21% undervalued after recent price drop

SD Biosensor, Inc. Proposes Discontuation of Use and Disposal of Specific Pilot COVID-19 At-Home Tests in the United States Due to Microbial Contamination in the Liquid Disposal Solution

Full year 2022 earnings: EPS and revenues miss analyst expectations

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners completed the acquisition of Meridian Bioscience, Inc. (NasdaqGS:VIVO) from Impactive Capital LP, BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc, Royce & Associates, LP and others.

Investor sentiment deteriorated over the past week

Now 21% undervalued after recent price drop

Price target decreased to ₩56,500

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners (collectively, the "Consortium") entered into a definitive merger agreement to acquire Meridian Bioscience, Inc. (NasdaqGS:VIVO) for $1.5 billion.

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Consensus revenue estimates increase by 17%

SD BioSensor, Inc (KOSE:A137310) agreed to acquire Relab S.R.L. for KRW 61.9 billion.

SD BioSensor, Inc (KOSE:A137310) acquired bestbion dx - Diagnostische Produkte und Beratung GmbH for KRW 16 billion.

Investor sentiment deteriorated over the past week

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines